Eastern Hepatobiliary Surgery Hospital
🇨🇳China
Transarterial Chemoembolization (TACE) Therapy of Hepatocellular Carcinoma (HCC) With Blocking Tumor Blood Temporarily and Enhancing Perfusion
Phase 1
Completed
- Conditions
- Hepatocellular Carcinoma
- First Posted Date
- 2009-01-22
- Last Posted Date
- 2016-04-01
- Lead Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Target Recruit Count
- 352
- Registration Number
- NCT00826384
- Locations
- 🇨🇳
Eastern hepatobilliary surgery hospital, Shanghai, Shanghai, China
A Prospective Randomized Trial Comparing Partial Hepatectomy and TACE Plus PEI for Small Hepatocellular Carcinoma
Not Applicable
Completed
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Other: operation;TACE plus PEI
- First Posted Date
- 2009-01-21
- Last Posted Date
- 2016-04-01
- Lead Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Target Recruit Count
- 160
- Registration Number
- NCT00825474
- Locations
- 🇨🇳
Eastern Hepatobiliary Surgery Hospital, Shanghai, Shanghai, China
Treatment of Portal Vein Tumor Thrombus After Hepatocellular Carcinoma Resection
Not Applicable
Completed
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Procedure: Laser ablation
- First Posted Date
- 2009-01-21
- Last Posted Date
- 2016-04-01
- Lead Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT00825669
- Locations
- 🇨🇳
Eastern Hepatobiliary Surgery Hospital, Shanghai, Shanghai, China
Efficacy and Significance of Antiviral Therapy for Unresectable Hepatitis B Virus-related Primary Liver Cancer
Not Applicable
Completed
- Conditions
- Primary Liver Cancer
- Interventions
- Drug: conventional therapy
- First Posted Date
- 2009-01-19
- Last Posted Date
- 2016-04-01
- Lead Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT00824707
- Locations
- 🇨🇳
Eastern Hepatobiliary Surgery Hospital, Shanghai, Shanghai, China
Research on Surgery and Micro-Invasive Treatment in Recurrent Primary Liver Cancer
Not Applicable
Completed
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Procedure: surgeryOther: PRFA or PMCT
- First Posted Date
- 2009-01-14
- Last Posted Date
- 2016-04-01
- Lead Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT00822562
- Locations
- 🇨🇳
Eastern Hepatobiliary Surgery Hospital, Shanghai, Shanghai, China
Pringle's Maneuver Versus Selective Hepatic Vascular Exclusion in Hepatectomy
Phase 2
Completed
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Procedure: Selective Hepatic Vascular ExclusionProcedure: Pringle's Maneuver
- First Posted Date
- 2009-01-12
- Last Posted Date
- 2016-04-01
- Lead Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Target Recruit Count
- 132
- Registration Number
- NCT00820339
- Locations
- 🇨🇳
Eastern hepatobilliary surgery hospital, Shanghai, Shanghai, China
Cytoreductive Surgery and Transarterial Chemoembolization (TACE) Versus TACE for Hepatocellular Carcinoma
Not Applicable
Completed
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Procedure: Cytoreductive SurgeryProcedure: TACE
- First Posted Date
- 2009-01-12
- Last Posted Date
- 2013-08-13
- Lead Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT00820157
- Locations
- 🇨🇳
Eastern Hepatobiliary Surgery Hospital, Shanghai, Shanghai, China
A Trial of Licartin for Preventing Tumor Recurrence After Liver Resection
Phase 2
Completed
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Drug: Licartin (generic name,[131I]metuximab injection)
- First Posted Date
- 2009-01-09
- Last Posted Date
- 2016-04-01
- Lead Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT00819650
- Locations
- 🇨🇳
Eastern hepatobilliary surgery hospital, Shanghai, Shanghai, China
A Trial of Adjuvant Transarterial Chemoembolization (TACE) for Preventing Tumor Recurrence After Liver Resection
- First Posted Date
- 2009-01-09
- Last Posted Date
- 2016-04-01
- Lead Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Target Recruit Count
- 450
- Registration Number
- NCT00820053
- Locations
- 🇨🇳
Eastern hepatobilliary surgery hospital, Shanghai, Shanghai, China
Intraoperative Chemotherapy Against Hepatocellular Carcinoma Recurrence
Not Applicable
Completed
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Drug: sustained released 5-FU and sustained released cisplatinDrug: sustained released 5-FUProcedure: TACE
- First Posted Date
- 2009-01-07
- Last Posted Date
- 2016-03-31
- Lead Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT00817895
- Locations
- 🇨🇳
Eastern Hepatobiliary Surgery Hospital, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath